1-8 of 8
Julie Brevard
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Jorge E. Cortes, Pierre Fenaux, Karen Yee, Christian Recher, Andrew H. Wei, Pau Montesinos, David C Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Pierre Peterlin, Olga Polyanskaya, Jennifer Sweeney, Julie Brevard, Emma Barrett, Stephane De Botton
Journal: Blood
Blood (2022) 140 (Supplement 1): 6193–6196.
https://doi.org/10.1182/blood-2022-167330
Published: 2022
Journal Articles

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Jorge E. Cortes, Jordi Esteve, Ashish Bajel, Karen Yee, Thorsten Braun, Stephane De Botton, Pierre Peterlin, Christian Recher, Xavier Thomas, Justin Watts, Montserrat Arnan Sangerman, Antonio Curti, Carolyn Grove, Brian A. Jonas, Francesco Lanza, Olivier Legrand, Pau Montesinos, Prapti Patel, Thomas Prebet, Eunice S. Wang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Pierre Fenaux, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 698.
https://doi.org/10.1182/blood-2021-144905
Published: 2021
Journal Articles

Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease

Ashutosh Lal, R. Clark Clark Brown, Thomas D. Coates, Theodosia A. Kalfa, Janet L. Kwiatkowski, Julie Brevard, Von Potter, Ken W. Wood, Sujit Sheth
Journal: Blood
Blood (2021) 138 (Supplement 1): 4162.
https://doi.org/10.1182/blood-2021-145752
Published: 2021
Journal Articles

An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)

Kenneth W. Wood, PhD, James Geib, BS, Eric Wu, PhD, Jason Berlin, MS, Irena Webster, MPH, MA, Kenneth I. Ataga, MD, Jo Howard, MBBChir, MRCP, FRCPath, Jeremie H. Estepp, MD, Marilyn J. Telen, MD, Julie Brevard, MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-134266
Published: 2020
Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 674.
https://doi.org/10.1182/blood-2019-124360
Published: 2019
Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Justin M. Watts, MD, Maria R. Baer, MD, Jay Yang, MD, Thomas Prebet, MD PhD, Sangmin Lee, MD, Gary J. Schiller, MD, Shira Dinner, MD, Arnaud Pigneux, Pau Montesinos, MD PhD, Eunice S. Wang, MD, Karen Seiter, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Stephane De Botton, Montserrat Arnan Sangerman, William B. Donnellan, MD, Brian A Jonas, MD PhD, Paul Brent Ferrell, Jr., MD, Kim-Hien Dao, DO, PhD, Patrick Kelly, MD, Jennifer Sweeney, Sanjeev Forsyth, Sylvie Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 231.
https://doi.org/10.1182/blood-2019-123920
Published: 2019
Journal Articles

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

Manish R. Patel, MD, Guillermo Garcia-Manero, MD, Ronald Paquette, MD, Shira Dinner, MD, William B. Donnellan, MD, Michael R. Grunwald, MD, Maria D Ribadeneira, PhD, Patricia Schroeder, Julie Brevard, Lindsey Wilson, Jennifer Sweeney, Patrick Kelly, MD, Jeffrey E. Lancet, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3907.
https://doi.org/10.1182/blood-2019-124741
Published: 2019
Journal Articles

Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

Sheeba K. Thomas, MD, Wael A. Harb, MD, Joseph Thaddeus Beck, MD, Gabrail Nashat, MD, M. Lia Palomba, MD, Stephen M Ansell, MD PhD, Herbert Eradat, MD, Edward N. Libby, III, MD, Ranjana H Advani, MD, Julio Hajdenberg, MD, Leonard T Heffner, MD, James Hoffman, MD, David H. Vesole, MD, Lindsey Simov, Nancy Wyant, Julie Brevard, MPH, James O'Leary, MD, Sudhir Agrawal, D.Phil
Journal: Blood
Blood (2015) 126 (23): 1540.
https://doi.org/10.1182/blood.V126.23.1540.1540
Published: 2015